Taras Petriv; Michael Tatarchuk; Oksana Rybachuk; Yulia Tsymbaliuk; Yaroslav Tsymbaliyk & Vitaliy Tsymbaliuk

Multiple sclerosis is a demyelinating disease of the nervous system that affects young people of working age and quickly leads to disability. Treatment of this pathology with umbilical cord mesenchymal stem cells is promising, given their immunomodulatory and neurotrophic properties. The study involved 27 patients diagnosed with multiple sclerosis, 12 of whom underwent combined treatment (intravenous and intrathecal administration) of umbilical cord multipotent mesenchymal stromal/stem cells. The effectiveness of treatment was determined by the degree of neurological deficit and spasticity. Combined treatment with umbilical cord mesenchymal stem cells significantly improves the condition of patients with multiple sclerosis and promotes the regression of neurological deficits and spasticity. This treatment is safe, but for a deeper study, it is necessary to continue research in this area.

KEY WORDS. Multipotent mesenchymal stem/stromal cells; Multiple sclerosis; Safety.

PETRIV, T.; TATARCHUK, M.; RYBACHUK, O.; TSYMBALIUK, Y.; TSYMBALIYK, Y. & TSYMBALIUK, V. Efficiency and safety of umbilical cord mesenchymal stromal/stem cells in multiple sclerosis combined treatment. Int. J. Morphol., 40(1):143-147, 2022.